机构:[1]Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China[2]Department of Anesthesiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China[3]Wenzhou Key Laboratory of Biophysics, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, China
The authors thank the project supported by Wenzhou Key Laboratory
of Biophysics (No. WIUCASSWWL22001) and the National Natural
Science Foundation of China (No.82172177).
第一作者机构:[1]Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China
通讯作者:
通讯机构:[1]Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China[3]Wenzhou Key Laboratory of Biophysics, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, China
推荐引用方式(GB/T 7714):
Wang Zhengyang,Guo Yanzhi,Li Kaiyin,et al.Targeting the PI3K/mTOR pathway in idiopathic pulmonary fibrosis: Advances and therapeutic potential[J].Bioorganic & Medicinal Chemistry.2024,115:117908.doi:10.1016/j.bmc.2024.117908.
APA:
Wang Zhengyang,Guo Yanzhi,Li Kaiyin,Huo Yan,Wang Shuyan...&Ma Mingliang.(2024).Targeting the PI3K/mTOR pathway in idiopathic pulmonary fibrosis: Advances and therapeutic potential.Bioorganic & Medicinal Chemistry,115,
MLA:
Wang Zhengyang,et al."Targeting the PI3K/mTOR pathway in idiopathic pulmonary fibrosis: Advances and therapeutic potential".Bioorganic & Medicinal Chemistry 115.(2024):117908